Yanauri Bravo

Prof. Yanauri Bravo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
YQYasmir J Quiroz
Yasmir J Quiroz
MMMarylu Mora
Marylu Mora
AVAlejandro Jose Vivas
Alejandro Jose Vivas
LPLenin Andres Gonzalez Paz
Lenin Andres Gonzalez Paz
YAYsaias J Alvarado
Ysaias J Alvarado
JPJosé Luis Paz
José Luis Paz
Background: Hypertension and Chronic Kidney Disease (CKD) are interconnected conditions, with the activation of the transcription factor NF-κB playing a crucial role. Sildenafil used for erectile dysfunction and pulmonary hypertension, may exhibit anti-inflammatory effects by interacting and modulating the structure of NF-κB. Methods: We employed various computational techniques to explore the interaction between sildenafil and NF-κB, including molecular docking, molecular dynamics (MD) simulations, elastic network models, statistical potentials, and volumetric analyses of internal cavities. Results: Sildenafil induces conformational changes in NF-κB, potentially reducing its activity. Molecular docking showed sildenafil’s inhibitory potency is comparable to known anti-inflammatory compounds like resveratrol. MD simulations indicated that sildenafil destabilizes NF-κB’s structure, which may impact its biological function. Experimental validation was conducted using biopsies from hypertensive and kidney-damaged rat models, treated and untreated with sildenafil. Histological and immunoperoxidase analyses assessed cellular infiltration, kidney damage, and NF-κB expression, demonstrated that sildenafil treatment significantly reduced cellular infiltration, kidney damage, and NF-κB expression, confirming its anti-inflammatory properties. Conclusion: sildenafil’s potential to modulate NF-κB activity, offering a promising therapeutic strategy for managing hypertension and CKD. These preliminary findings suggest that sildenafil could be repurposed to provide comprehensive treatment for these conditions, leveraging its molecular and biochemical interactions with NF-κB.